Certificate PL-26-00128 · AC-262 10 mg Capsules · lot PL-2610-005 · branded for Epic Wholesalers LLC -dba-Epic Peptides Lab
VerifyCertificate page
Epic Wholesalers LLC -dba-Epic Peptides Lab
Epic Wholesalers LLC -dba-Epic Peptides Lab
Certificate of Analysis · Lot release
www.epicpeptideslab.com
Certificate no.
PL-26-00128
Verification key
EPWVTQEK
Scan or enter both at
prymalab.net/testing/verify

Certificate of Analysis · Lot release · Issued for Epic Wholesalers LLC -dba-Epic Peptides Lab

AC-262 10 mg Capsules

Lot PL-2610-005 · Capsules · Label claim 10 mg per capsule
Tested in-house by PrymaLab
In-house analytical result,
not an independent third-party test
Lot / batch number
PL-2610-005
Date made
2026-10-01
Date of analysis
2026-10-02
Date issued
2026-10-08
Retest / expiry
2028-10-01
Units in lot / sampled
379 / 2
Storage
—
Certificate type
Lot COA, 2 pages
Compound
AC-262
CAS number
870888-46-3
Molecular formula
C18H18N2O
Theoretical mass (avg.)
278.35 Da
Structure
Purity · RP-HPLC, area %
99.78%
Specification ≥ 99.0% • main peak at 9.81 min
Identity · Observed Mass
278.36 Da
Theoretical 278.35 Da • +0.01 Da (36 ppm)
Overall conclusion
PASS
Meets every specification for the tests performed
TestMethodSpecificationResultConclusion
Identity (mass)LC-MS, ESI positiveTheoretical ± 1.0 Da278.36 DaPASS
PurityRP-HPLC, UV 254–306 nm, area%≥ 99.0%99.78%PASS
Largest impurityRP-HPLC, area%≤ 1.0%0.09% (RT 10.90)PASS
Capsule contentContent vs label claim9–11 mg/cap10.20 mg/capPASS
Bacterial endotoxinLAL, kinetic——N/A
Aerobic count (TAMC)USP <61>< 10 CFU/g< 10 CFU/gPASS
Yeast & mold (TYMC)USP <61>< 10 CFU/g< 10 CFU/gPASS
E. coliUSP <62>AbsentAbsentPASS

1HPLC chromatogram

Data file: PL-2610-005-HPLC.raw · Column C18, 150 × 4.6 mm · UV 254–306 nm
0.01%0.1%1%10%100%7891011121314Retention time (min) · stick height = area % (log scale)99.78% · 9.81 min0.06% †0.09% †0.07% †
Peak plot drawn from the integrated peak table (area %, log scale); it is not the instrument trace, which is retained in PL-2610-005-HPLC.raw. † Nominal reference retention time for the assigned impurity; the main-peak RT is observed in this lot.
Epic Wholesalers LLC -dba-Epic Peptides Lab
Epic Wholesalers LLC -dba-Epic Peptides Lab
Certificate of Analysis · continued
AC-262 10 mg Capsules · Lot PL-2610-005 · Certificate PL-26-00128
Lot PL-2610-005
Method, peak table and approval

2HPLC method · PL-2610-005-HPLC.raw

Instrument
Waters Alliance e2695
Data System
Empower 3
Detector
UV absorbance
Detection Wavelength
254–306 nm
Column
C18, 150 × 4.6 mm, 3.5 µm
Mobile Phase A
0.1% TFA in water
Mobile Phase B
0.1% TFA in MeCN
Gradient
5–95% B over 25 min (linear)
Flow Rate
1.0 mL/min
Column Temperature
40 °C
Injection Volume
10 µL

3Gradient program

Time (min)% A% B
0.0955
25.0595

4Peak table

PeakRT (min)AreaArea %
18.40 †—0.06
29.81—99.78
310.90 †—0.09
412.10 †—0.07
Total—100.00
Peaks: 1 unidentified impurity; 2 main peak (AC-262); 3 unidentified impurity; 4 unidentified impurity · Area % from the integrated peak table (absolute areas are not part of the lot-release export) · † nominal reference RT for the assigned impurity · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.

5Identity by mass spectrometry

Instrument
Waters SQD
Ionization / Mode
ESI, positive
Reference m/z (ion)
279.36 [M+H]+
Deconvoluted Mass
278.36 Da
Theoretical Mass
278.35 Da
Difference
+0.01 Da (36 ppm)
Data File
PL-2610-005-MS.d
Acceptance
Within ± 1.0 Da

6Additional tests

TestPerformed byDateReport / file
Content vs label claimPrymaLab Analytical2026-10-02—
Microbial limits (USP <61>/<62>)PrymaLab Analytical2026-10-08—
A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.

7Review and approval

D. Reynolds
Analyst · performed the testing
Date: 2026-10-08
S. Calloway
Reviewer · checked against raw data
Date: 2026-10-08
M. Phelps
Lab Director · approved for release
Date: 2026-10-08